References
- Lee L, Gupta M, Sahasranaman S. Immune checkpoint inhibitors: an introduction to the next-generation cancer immunotherapy. J Clin Pharmacol. 2016;56(2):157–69. doi:https://doi.org/10.1002/jcph.591.
- Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375–84. doi:https://doi.org/10.1016/S1470-2045(15)70076-8.
- Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–32. doi:https://doi.org/10.1056/NEJMoa1503093.
- Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–1271. doi:https://doi.org/10.1056/NEJMoa1504030.
- Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–28. doi:https://doi.org/10.1056/NEJMoa1501824.
- Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13. doi:https://doi.org/10.1056/NEJMoa1510665.
- Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26(12):2375–91. doi:https://doi.org/10.1093/annonc/mdv383.
- Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of Immunotherapy for the practitioner. J Clin Oncol. 2015;33(18):2092–9. doi:https://doi.org/10.1200/JCO.2014.60.0379.
- Nelson JD, Helms H, Fiscella R, Southwell Y, Hirsch JD. A new look at dry eye disease and its treatment. Adv Ther. 2000;17(2):84–93. doi:https://doi.org/10.1007/BF02854841.
- Lemp MA. Report of the national eye institute/industry workshop on clinical trials in dry eyes. Clao J. 1995;21(4):221–32.
- Warner BM, Baer AN, Lipson EJ, Allen C, Hinrichs C, Rajan A, et al. Sicca syndrome associated with immune checkpoint Inhibitor Therapy. Oncologist. 2019;24(9):1259–69. doi:https://doi.org/10.1634/theoncologist.2018-0823.
- Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA. Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects. Retina. 2018;38(6):1063–78. doi:https://doi.org/10.1097/IAE.0000000000002181.
- Holly FJ, Lamberts DW, Esquivel ED. Kinetics of capillary tear flow in the Schirmer strip. Curr Eye Res. 1982;2(1):57–70. doi:https://doi.org/10.3109/02713688208998380.
- Vıtalı C, Bombardıerı S, Jonsson R, et al. European Study Group On Classification Criteria For Sjogren’s, S. Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554–8.
- Greenspan JS, Daniels TE, Talal N, Sylvester RA. The histopathology of Sjögren’s syndrome in labial salivary gland biopsies. Oral Surg Oral Med Oral Pathol. 1974;37(2):217–29. doi:https://doi.org/10.1016/0030-4220(74)90417-4.
- Tarpley TM, Jr, Anderson LG, White CL. Minor salivary gland involvement in Sjögren's syndrome. Oral Surg Oral Med Oral Pathol. 1974;37(1):64–74. doi:https://doi.org/10.1016/0030-4220(74)90160-1.
- Daniels TE, Silverman S, Jr, Michalski JP, Greenspan JS, Sylvester RA, Talal N. The oral component of Sjögren’s syndrome. Oral Surg Oral Med. Oral Surg Oral Med Oral Pathol. 1975;39(6):875–85. doi:https://doi.org/10.1016/0030-4220(75)90108-5.
- Young L, Finnigan S, Streicher H, Chen HX, Murray J, Sen HN, et al. Ocular adverse events in PD-1 and PD-L1 inhibitors. J Immunother Cancer. 2021;9(7):e002119. doi:https://doi.org/10.1136/jitc-2020-002119.
- National Comprehensive Cancer Network Guidelines, Management Of Immunotherapy-Related Toxicities Guideline, ms-25,26. https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf.
- Hıgashı T, Mıyamoto H, Yoshıda R, et al. A case of Sjögren’s syndrome as an immune-related adverse event of nivolumab treatment for gastric cancer. Intern Med. 2020;59:2499–504.
- Cappelli LC, Gutierrez AK, Baer AN, Albayda J, Manno RL, Haque U, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis. 2017;76(1):43–50. doi:https://doi.org/10.1136/annrheumdis-2016-209595.
- Ramos-Casals M, Marıa A, Suárez-Almazor ME, et al. Sicca/Sjögren’s syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR). Clin Exp Rheumatol. 2019;118:114–22.
- Chrıstodoulou MI, Kapsogeorgou EK, Moutsopoulos HM. Characteristics of the minor salivary gland infiltrates in Sjögren’s syndrome. J Autoimmun. 2010;34(4):400–7. doi:https://doi.org/10.1016/j.jaut.2009.10.004.
- Bitton K, Michot J-M, Barreau E, Lambotte O, Haigh O, Marabelle A, et al. Prevalence and clinical patterns of ocular complications associated with anti-PD-1/PD-L1 anticancer immunotherapy. Am J Ophthalmol. 2019;202:109–17. doi:https://doi.org/10.1016/j.ajo.2019.02.012.
- Abdel-Rahman O, Oweira H, Petrausch U, Helbling D, Schmidt J, Mannhart M, et al. Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review. Expert Rev Anticancer Ther. 2017;17(4):387–94. doi:https://doi.org/10.1080/14737140.2017.1296765.
- Losonczy G, Gijs M, Nuijts RMMA. Nivolumab-induced ulcerative keratitis-a case report. Cornea. 2021;40(5):656–8. doi:https://doi.org/10.1097/ICO.0000000000002460.
- Eigentler TK, Hassel JC, Berking C, Aberle J, Bachmann O, Grünwald V, et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev. 2016;45:7–18. doi:https://doi.org/10.1016/j.ctrv.2016.02.003.
- Ortiz Brugués A, Sibaud V, Herbault-Barrés B, et al. Sicca syndrome induced by immune checkpoint inhibitor therapy: optimal management still pending. Oncologist. 2020;25(2):391–5.
- Warner B, Baer A. In Reply. Oncologist. 2020;25(2):e396–e397. doi:https://doi.org/10.1634/theoncologist.2019-0515.